Key Highlights
- 1.2 million new covered lives are expected from commitments to date and anticipated remaining decisions, Progyny (NASDAQ:PGNY) said on October 7, 2026, with launches through the first half of 2027.
- 6.75% was the rise to USD 27.66 in published market data on October 7, 2026, a larger gain than the 5.8% in the headline, on a Market Value near USD 2.12 billion.
- USD 350.5 million of second quarter revenue, up 5.3% as reported or about 11% excluding a transition agreement, produced record adjusted EBITDA of USD 62.1 million for Progyny.
- USD 1.36 billion to USD 1.385 billion is Progyny's 2026 Revenue guidance, with adjusted EBITDA of USD 233 million to USD 240 million and diluted EPS of USD 1.26 to USD 1.32.
The October 7 Selling Season Update
Progyny (NASDAQ:PGNY) issued a company release on October 7, 2026 titled as selling season pacing to a record level. It said 1.2 million new covered lives are expected from commitments to date and anticipated remaining decisions, with launches through the first half of 2027. CEO Pete Anevski said the season was pacing to a potential record level of new lives for its managed fertility solution. Published market data showed the shares up about 6.75% to USD 27.66, against 5.8% in the headline. An initiation with a USD 37 target, cited in early reports, could not be verified. The company also said it offers accelerated contracting and streamlined implementation for employers that want to add coverage, which supports the pacing claim.
What Covered Lives Mean for Revenue
A covered life is a member of an employer plan with access to Progyny's fertility and family building benefit. Revenue follows utilization of that benefit and pharmacy spend, not enrollment alone, so a record sales season lifts future revenue only as members use services after launch. On the August 6, 2026 second quarter call, management had already targeted more than 1 million new lives for 2027. The new figure of 1.2 million is higher, though still described as commitments plus anticipated decisions. Second quarter fertility benefit revenue rose 7.6% to USD 230.2 million, while pharmacy revenue rose 1.2% to USD 120.3 million. Client count reached 604 from 542 a year earlier, and average members rose to about 7.19 million.
Risks, Buybacks and What to Watch
Risks include the word potential in the record claim, pending employer decisions, flat assisted reproductive technology cycles of 16,998 and the transition agreement that cut reported growth. Progyny bought back 1.2 million shares for USD 31.5 million in the second quarter, and 10.8 million since November 2025, shrinking the share count by about 12.5%. Published market data show a 52-week range of USD 16.10 to USD 33.07, a trailing P/E near 30 and an average analyst target near USD 34.42. Third quarter results, guided to revenue of USD 335 million to USD 345 million, are expected in early November 2026; the date is unconfirmed. A shortfall against commitments would be the main swing factor.
Where Things Stand
Progyny (NASDAQ:PGNY) shares rose on October 7, 2026 mainly because the company itself said its selling season was pacing toward a record, with 1.2 million new covered lives expected. That is a sales signal, not a revenue result, and the new analyst coverage cited in early reports was not verified. The company also has record second quarter revenue, rising client counts and active buybacks behind it, but modest pharmacy growth and flat cycles show where caution belongs until 2027 launches begin.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...